While, all the modalities of KRTs play a role in the treatment of patients with compensated and decompensated liver disease with renal dysfunction, they are restricted to removing small, water-soluble molecules that are not substantially bound to plasma proteins and thus of limited efficacy in removing the common toxins associated with liver failure, which are predominantly hydrophobic molecules carried by albumin (13),. This evidence concerns the gene ALB and liver failure.